John W. Kozarich - May 16, 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John W. Kozarich
Stock symbol
LGND
Transactions as of
May 16, 2023
Transactions value $
-$343,081
Form type
4
Date filed
5/18/2023, 05:18 PM
Previous filing
May 10, 2023
Next filing
Jun 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Sale -$343K -4.44K -10.35% $77.20 38.5K May 16, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.20 to $77.24. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein.